CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $106 million in its first quarter.On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.79.The results met Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was also for a loss of $1.79 per share.The cancer drug developer posted revenue of $62.7 million in the period, surpassing Street forecasts. Eight analysts surveyed by Zacks expected $43.2 million.Blueprint Medicines expects full-year revenue in the range of $180 million to $200 million.Blueprint Medicines shares have fallen 44% since the beginning of the year. The stock has declined 38% in the last 12 months._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC